Lv1
32 积分 2021-05-25 加入
Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer: A Randomized Clinical Trial
23天前
已完结
Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer
1个月前
已完结
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
2个月前
已完结
Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer
2个月前
已完结
Integrative analysis of RiboSis-related gene expression in colorectal cancer: implications for prognosis and immunotherapy
3个月前
已完结
Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway
3个月前
已完结
Multi-omics analysis revealed heterogeneity of AARS1 and AARS2 in pan-cancer and identified AARS1 as a potential prognostic biomarker for urologic neoplasms
3个月前
已完结
Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer
3个月前
已完结
A TROP2-targeting ADC synergizes with oxidative phosphorylation inhibitor to enhance apoptosis in ESCC by suppressing the PI3K-AKT-mTOR signaling pathway
3个月前
已完结
Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders
3个月前
已完结
皖公网安备34019202002308
